Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

Br J Haematol. 2022 Jan;196(2):437-440. doi: 10.1111/bjh.17792. Epub 2021 Aug 25.

¹ Department of Oncology, Lund University, Skane University Hospital, Lund, Sweden.
² Division of Clinical Epidemiology, Department of Medicine Solna, Karolinska Institute, Stockholm, Sweden.
³ Department of Hematology, Halmstad Hospital, Halmstad, Sweden.
⁴ Department of Medicine Solna, Division of Hematology, Karolinska Institute and Karolinska University Hospital, Stockholm, Sweden.
⁵ Division of Drug Research, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden.
⁶ Department of Haematology, Odense University Hospital, Odense, Denmark.
⁷ Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.
⁸ Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.

No abstract available

Keywords: Idelalisib; relapsed/refractory DLBCL; transformed lymphoma.

Publication types